Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)
- Conditions
- Breast Cancer
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 629
- Registration Number
- NCT02913456
- Locations
- 🇧🇬
MHAT Nadezhda, Sofia, Bulgaria
🇦🇹Klinikum Klagenfurt; Abt. f. Hämatologie u. internistische Onkologie, Klagenfurt, Austria
🇧🇬Mdozs - Russe, Ruse, Bulgaria
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 231
- Registration Number
- NCT02908685
- Locations
- 🇯🇵
Minami Kyushu National Hospital, Kagoshima, Japan
🇯🇵Miyagi Children's Hospital, Miyagi, Japan
🇯🇵Shiga Medical Center for Children, Shiga, Japan
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 514
- Registration Number
- NCT02908672
- Locations
- 🇺🇸
St. Luke's University Health network, Bethlehem, Pennsylvania, United States
🇫🇷Institut Gustave Roussy; Dermatologie, Villejuif, France
🇩🇪Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, Germany
A Non-Interventional Safety Study of Balsamic Bactrim
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02902640
- Locations
- 🇵🇪
Clinica San Borja; Instituto de Enfermedades Respiratorias EFEH, Lima, Peru
🇵🇪Clinica de Especialidades Medicas, Lima, Peru
🇵🇪Centro de Investigaciones Medicas/Hospital Maria Auxiliadora, San Juan de Miraflores, Peru
A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)
- Conditions
- Autism Spectrum Disorder
- Interventions
- Drug: RO5285119Drug: Placebo
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 339
- Registration Number
- NCT02901431
- Locations
- 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸University Hospitals, Cleveland, Ohio, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 243
- Registration Number
- NCT02896855
- Locations
- 🇨🇳
the First Hospital of Jilin University, Changchun, China
🇨🇳Changzhou First People's Hospital, Changzhou, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai City, China
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT02892318
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸City of Hope, Duarte, California, United States
A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02882009
- Locations
- 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States
A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT02879981
- Locations
- 🇵🇪
Hospital Emergencias Pediatricas; Unidad de Investigación Pediátrica, La Victoria, Peru
🇵🇪Clínica Anglo Americana-CENTRO DE INVESTIGACION PEDIATRIA CAA, San Isidro, Peru
🇵🇪Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional, Lima, Peru
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT02876224
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University Of Colorado, Aurora, Colorado, United States
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain